SynthesisFrontiers in medicine2026
Esketamine for negative emotions and cognitive function in general anesthesia: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aims to systematically evaluate, through a systematic review and meta-analysis, the effect of esketamine on postoperative negative emotions (anxiety and depression) and cognitive function in patients undergoing general anesthesia. Methods: Following PRISMA guidelines, we systematically searched PubMed, Web of Science, Embase, Cochrane Library, and CNKI to identify studies up to April 2025. Included randomized controlled trials (RCTs) involved adults undergoing general anesthesia, comparing perioperative esketamine to placebo/standard care, and reporting outcomes on negative emotions or cognitive function. Risk of bias was evaluated using Cochrane RoB 2.0, and Data were synthesized using R 4.3.3 with random-effects models; heterogeneity and robustness were assessed via I Results: Thirteen RCTs involving 1,312 patients were included. Esketamine significantly reduced depressive (SMD = -0.92, 95% CI: [-1.39, -0.46]) and anxiety symptoms (SMD = -1.23, 95% CI: [-1.71, -0.75]), with low certainty of evidence for both outcomes. Cognitive outcomes were heterogeneous: MMSE showed no significant effect overall (SMD = 0.22, 95% CI: [-0.87, 1.30]) but became significant after excluding an outlier (SMD = 0.65, 95% CI: [0.39, 0.90]), while MoCA results remained non-significant (SMD = 0.93, 95% CI: [-0.99, 2.84]), and the certainty of evidence for MMSE and MoCA was rated very low. Conclusion: Esketamine demonstrates robust antidepressant and anxiolytic effects postoperatively, while its cognitive benefits remain unclear owing to high heterogeneity and very low evidence certainty. Although these findings support the potential application of esketamine in perioperative emotional management, the low to very low overall certainty of evidence justifies the need for further high-quality, large-scale RCTs to clarify its cognitive effects and establish optimal dosing regimens. Systematic review registration: Identifier, CRD420251078985.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.